Weekly Recap | GUSHENGTANG -8.54%, most brokers rate it buy

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

Gushengtang (2273.HK) fell 8.54% this week to close at HK$26.56, underperforming the Hang Seng Index by 2.89 percentage points. Trade spanned four sessions, opening Monday at HK$28.98 and drifting lower each day to finish near the weekly low of HK$26.42 on Thursday. Volume ran slightly above its recent median, with no major catalysts shaping the tape.

Analyst Ratings

Nineteen brokers cover the name, with 18 at buy or overweight and one at sell. The consensus rating is strong buy, and the average target sits at HK$40.22, roughly 51.4% above the current price. Targets range from HK$25.29 to HK$60.15, a wide spread. Gushengtang ranks first among eight names in its healthcare services peer group.

The Week Ahead

Gushengtang reports fiscal Q3 2026 results on Friday, 27 November 2026. The focus will be on quarterly revenue and profit growth against the prior year. Fiscal 2026 full-year results are scheduled for Tuesday, 30 March 2027, with consensus estimates pointing to EPS of HK$2.16, up about 20.5% year on year.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.